Flexible Flat-Rate Plans
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
DrugPatentWatch Database Preview
Lubiprostone - Generic Drug Details
« Back to Dashboard
This ingredient has one hundred and eighty patent family members in twenty-six countries.
There are seven drug master file entries for lubiprostone. Six suppliers are listed for this compound.
Summary for Generic Name: lubiprostone
| Tradenames: | 1 |
| Patents: | 16 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: see list | 7 |
| Suppliers / Packaging: see list | 6 |
| Therapeutic Class: | Gastrointestinal Agents |
| Drug Prices: | see low prices |
Pharmacology for Ingredient: lubiprostone
| Drug Class | Chloride Channel Activator |
| Mechanism of Action | Chloride Channel Activators |
Clinical Trials for: lubiprostone
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | RX | Yes | 8,097,653 | Nov 14, 2022 | ||||||||||||||||||||
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | RX | No | 7,064,148 | Aug 30, 2022 | ||||||||||||||||||||
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | RX | Yes | 8,026,393 | Oct 25, 2027 | Y | |||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Expired Orange Book Patents for Generic Ingredient: lubiprostone
These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | 5,284,858 | <disabled> | ||||||||||||||||||||||
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | 5,284,858 | <disabled> | ||||||||||||||||||||||
Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | 5,317,032 | <disabled> | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Non-Orange Book Patents for Generic Ingredient: lubiprostone
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,748,454 | Anti-constipation composition | <disabled in preview> | |||||||||||||||||||||||||||
| 6,923,654 | Manikin and eye device apparatus, methods and articles of manufacture | <disabled in preview> | |||||||||||||||||||||||||||
| 7,253,295 | Chloride channel opener | <disabled in preview> | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
International Patent Family for Ingredient: lubiprostone
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Argentina | 050626 | <disabled in preview> | |||||||||||||||||||||||||||
| Hungary | 0203746 | <disabled in preview> | |||||||||||||||||||||||||||
| Czech Republic | 303625 | <disabled in preview> | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Supplementary Protection Certificates for Tradename: LUBIPROSTONE
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 00757 | Netherlands | <disabled> | PRODUCT NAME: LUBIPROSTON; NAT. REGISTRATION NO/DATE: RVG 115891 20150317; FIRST REGISTRATION: | ||||||||||||||||||||||||||
| 1315485/01 | Switzerland | <disabled> | FORMER REPRESENTATIVE: BOHEST AG, CH | ||||||||||||||||||||||||||
| /2015 | Austria | <disabled> | PRODUCT NAME: LUBIPROSTON UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; NAT. REGISTRATION NO/DATE: 136176 20150508; FIRST REGISTRATION: GB PL 21341/0003 20120910 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
For more information try a trial or see the database preview and plans and pricing
How are People Using DrugPatentWatch?
For patent and exclusivity due dligience
— Pharma investment firm, USA
To get information on brands we work on currently or could potentially work on
— Marketing professional, USA
To know more about patents of drug products and drug substances
— Manager, formulation R&D, India
To study patents on drugs in selected therapeutic areas
— Pharmaceutical process development, India
To get paragraph IV challenges, detailed regulatory status and tentative approvals
— Dosage form R&D services company, India
For data on generic availability, patent expirations, legal action that postpones generic launch
— Clinical pharmacist, USA
To analyze generic candidates using patent expiration data
— Portfolio management, Indonesia
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639
